Clinical Trial

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The main consideration is the allocation of company resources, We can only terminate this research.
Summary
This is a single-center, open-label study conducted in subjects with relapsed or refractory CD30-positive lymphoma, with priority given to Hodgkin lymphoma and anaplastic large cell lymphoma.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Withdrawn 2026-05-07
critical Reason stopped changed: — → The main consideration is the allocation of company resources, We can only terminate this research. 2026-05-07
notable Enrollment reduced: 18 -> 0 participants 2026-05-07
Trial Details
NCT Number NCT07453446
Lead Sponsor Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Conditions Relapsed or Refractory Lymphoma
Start Date 2025-03-04
Primary Completion 2027-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-06